News

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1 — currently being developed by CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

In planned U.S. and EU trials, CureLab will offer Elenagen for 24 months, as data suggests further treatment may offer no additional benefit.

Os pesquisadores avaliaram uma nova terapia baseada em DNA, Elenagen, administrada em combinação com a quimioterapia padrão gencitabina em mulheres com PROC e CA-125 elevado.

Elenagen is a plasmid therapy—a small, circular piece of DNA encoding the protein p62/SQSTM1—currently being developed by CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection.

Elenagen, a DNA-based therapy, works by targeting specific genetic pathways involved in cancer progression.